Actively Recruiting

Phase 3
Age: 12Years - 65Years
All Genders
NCT04898283

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Led by Inmunotek S.L. · Updated on 2025-05-13

180

Participants Needed

27

Research Sites

278 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.

CONDITIONS

Official Title

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Who Can Participate

Age: 12Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent
  • Aged between 12 and 65 years, any gender
  • Clinical history of intermittent or persistent moderate to severe rhinitis or rhinoconjunctivitis with or without moderate intermittent or persistent asthma caused by grass and cupressaceae pollen
  • Positive skin prick test with wheal size greater than 5 mm to standardized grass or cupressaceae pollen extracts, with papule diameter equal or larger than histamine control
  • Specific IgE levels above 3.5 KU/L against grass and cupressaceae pollen
  • Negative pregnancy test for women of childbearing age at trial start
  • Women of childbearing potential must agree to use accepted contraception methods
  • Ability to comply with dosing regimen
  • Ownership of a smartphone for symptom and medication recording
  • Negative prick tests to co-seasonal pollens with specific IgE below 3.5 KU/L and no relevant symptoms
  • Negative prick tests to other aeroallergens including dust mites, epitheliums, and fungus, with specific IgE below 3.5 KU/L and no relevant symptoms
Not Eligible

You will not qualify if you...

  • Positive prick test to aeroallergens other than pollen with exceptions for occasional epithelia exposure
  • Prior allergen immunotherapy within 5 years or current immunotherapy
  • Contraindications to immunotherapy as defined by allergy societies
  • Severe or uncontrolled asthma with FEV1 below 70% despite treatment
  • Severe rhinitis or rhinoconjunctivitis requiring ongoing oral or systemic antihistamines
  • Severe reactions to diagnostic skin prick tests
  • Treatment with beta-blockers
  • Clinically unstable conditions such as acute asthma, infections, or urticaria
  • Active chronic urticaria, severe skin conditions, or history of hereditary angioedema
  • Conditions contraindicating adrenaline use like hyperthyroidism, hypertension, or heart disease
  • Serious unrelated diseases that may affect treatment or follow-up
  • Autoimmune diseases, tumors, or immunodeficiencies
  • Severe psychiatric disorders or inability to cooperate
  • Allergy to components of the investigational product other than allergens
  • Lower respiratory diseases other than asthma
  • Direct relatives of study researchers
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 27 locations

1

Hospital Recoletas Felipe Ii

Valladolid, Castille and León, Spain, 47003

Actively Recruiting

2

Cedt de Tarancón

Tarancón, Cuenca, Spain, 16400

Actively Recruiting

3

Hospital Universitario Principe de Asturias

Alcalá de Henares, Madrid, Spain, 28806

Completed

4

Hospital U. Fundación Alcorcón

Alcorcón, Madrid, Spain, 28922

Actively Recruiting

5

Hospital Cruz Roja Madrid

Madrid, Madrid, Spain, 28003

Actively Recruiting

6

Clínica Privada Dres Ojeda

Madrid, Madrid, Spain, 28006

Actively Recruiting

7

Hospital Universitario Puerta de Hierro

Majadahonda, Madrid, Spain, 28222

Not Yet Recruiting

8

Clínica Privada Murcia

Murcia, Murcia, Spain, 30006

Not Yet Recruiting

9

Hospital Nuestra Señora de Sonsoles

Ávila, Spain, 05071

Not Yet Recruiting

10

Fundación Hospital Sant Pere Claver

Barcelona, Spain, 08004

Withdrawn

11

Clínica privada Burgos

Burgos, Spain, 09004

Withdrawn

12

Hospital Universitario de Burgos

Burgos, Spain, 09006

Actively Recruiting

13

Hospital General de Villalba

Collado Villalba, Spain, 28400

Not Yet Recruiting

14

Clinica privada

León, Spain, 24003

Withdrawn

15

Clínica Subiza

Madrid, Spain, 28006

Active, Not Recruiting

16

Hospital Carlos III (antiguo CAP José Marva)

Madrid, Spain, 28029

Withdrawn

17

Clínica Privada

Madrid, Spain, 28034

Withdrawn

18

Hospital Universitario Ramón y Cajal

Madrid, Spain, 28034

Not Yet Recruiting

19

Hospital Universitario Fundación Jiménez Díaz

Madrid, Spain, 28040

Actively Recruiting

20

Hospital Infanta Elena

Madrid, Spain, 28342

Not Yet Recruiting

21

Centro médico Saluddia

Madrid, Spain, 28522

Actively Recruiting

22

Centro Médico Iza (Clínica Privada Madrid)

Madrid, Spain, 28760

Actively Recruiting

23

Consulta Privada

Palencia, Spain, 34001

Completed

24

Hospital Clínico de Salamanca

Salamanca, Spain, 37007

Active, Not Recruiting

25

Hospital General Universitario de Segovia

Segovia, Spain, 40002

Not Yet Recruiting

26

Clinica Privada Soria

Soria, Spain, 42005

Withdrawn

27

Clínica Privada

Zaragoza, Spain, 50004

Withdrawn

Loading map...

Research Team

M

Miguel Casanovas, MD PhD

CONTACT

R

Raquel Caballero

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here